MEDICOVER GENETICS

PLACING GENETICS AT THE CORE OF MEDICAL DECISIONS

Oncology Portfolio

www.medicover-genetics.com

Medicover Genetics oncology portfolio offers a wide range of tests that empower healthcare providers to identify the best solution for their patients. Our expertise in oncology and unique technology enables the development of highly accurate tests including hereditary cancer, tumor profiling and liquid biopsy tests that can maximize the possibilities of successful treatment, identify prophylactic measures for effective preventative actions, and improve prognosis.

LIQUID BIOPSY
Therapy re-evaluation

SOMATIC TUMOR PROFILE
Diagnosis & therapy identification

HEREDITARY CANCER
Early detection of cancer risk

LIQUID BIOPSY

A non-invasive blood test that identifies the genetic characteristics of primary and metastatic tumors. It guides therapy selection and re-evaluation for therapy resistance, and offers novel immunotherapy options for treatment.

BENEFITS OF LIQUID BIOPSY

- Non-invasive and safe for patients
- Identifies tumor heterogeneity of primary tumors and metastatic lesions
- Easily repeatable and convenient for the patient
- Available for patients who are not eligible or unfit for another tumor biopsy
- Enables evaluation of tumor genetic profile for therapy selection at frequent intervals (during disease progression or therapy resistance)

NeoThetis

Blood sample

6-9 days

EXTENDED TESTS

- Pan-Cancer Plus — *222 genes, analysis of MSI and bTMB*
- Pan-Cancer — *80 genes, analysis of MSI*

CANCER-SPECIFIC TESTS

- NeoThetis Breast/Gynecological — *48 genes*
- NeoThetis Colorectal — *34 genes*
- NeoThetis Gastric — *23 genes*
- NeoThetis Melanoma — *28 genes*
- NeoThetis NSCLC — *36 genes*
- NeoThetis Pancreatic — *26 genes*
- NeoThetis Prostate — *35 genes*

UNIQUE FEATURES

Immunotherapy eligibility:
Immunotherapy biomarkers, such as TMB and MSI, are assessed. FDA/EMA approved immunotherapy options can be available depending on the type of tumor.

Tumor Mutational Burden (TMB):
TMB is an independent, tumor agnostic biomarker. It measures the total number of mutations per megabase and identifies patients eligible for specific immunotherapy treatment.
Blood TMB (**bTMB**), is an emerging biomarker that is analysed from the circulating tumor DNA released in the blood from tumors.

ForeSENTIA, Detect&Act, NeoThetis

Microsatellite Instability (MSI):
Identifies mutation frequency within satellites (short, repeated DNA sequences of DNA). It can have therapeutic and prognostic value for patients with solid tumors who present high MSI status.

ForeSENTIA, Detect&Act, NeoThetis

SOMATIC TUMOR PROFILE

Tests that identify the genetic and molecular characteristics of tumors by analysing tissue samples from tumor biopsy. They guide precise therapy selection, enabling for novel immunotherapy options.

BENEFITS OF SOMATIC TUMOR PROFILE

- Deep analysis of tumor molecular characteristics
- Identifies tumor heterogeneity, based on the biopsied area
- Identifies the genetic alterations and immunotherapy biomarkers involved in cancer development and resistance
- Guides precision medicine and personalised treatment options depending on the type of tumor
- Improves the clinical management and disease classification

ForeSENTIA

FFPE tissue sample from a biopsy

10-15 days

PAN-CANCER TESTS

- Pan-Cancer Advanced *(392 genes, analysis of MSI and TMB)*
- Pan-Cancer Plus *(222 genes, analysis of MSI and TMB)*
- Pan-Cancer Core *(80 genes, analysis of MSI)*

CANCER-SPECIFIC TESTS

- Breast/Gynecological *48 genes*
- Colorectal *34 genes*
- Lung (NSCLC) *36 genes*
- Prostate *36 genes*
- Melanoma *22 genes*
- Glioma *22 genes*

GENE-FOCUSED TESTS

- BRAF
- EGFR
- IDH1 & IDH2
- KRAS & NRAS
- PIK3CA & AKT1

Histology available upon request

Detect&Act

FFPE tissue sample from a biopsy

Histopathology analysis: 7-10 days
Genetic analysis: 7-20 days

COMPREHENSIVE TEST

>638 DNA-based gene analysis, 22 RNA-based gene analysis for rearrangement detection and splicing events, MSI, TMB, HRD

TARGETED-THERAPY TESTS

Combines histopathology and targeted genetic testing, including DNA-based gene analysis, MSI, and fusion genes

• Breast carcinoma • Colon carcinoma • Endometrial carcinoma • Gastrointestinal stromal tumors (GIST) • Glioblastoma • Melanoma • Non-small cell lung carcinoma • Ovarian carcinoma • Pancreatic carcinoma • Prostate carcinoma • Urothelial carcinoma

ANALYSIS OF REARRANGEMENTS

- Solid tumors general *121 genes*
- Sarcoma *up to 26 genes*

Eligibility on clinical trials:
Tested genes and genomic signatures serve as selection criteria in ongoing clinical trials.

ForeSENTIA, Detect&Act, NeoThetis

Clinically relevant genes:
The genetic alterations tested are included in clinical practice guidelines and are recommended by professional bodies such as NCCN, ESMO and ASCO.

ForeSENTIA, Detect&Act, NeoThetis, PreSENTIA, Predict&Prevent

HEREDITARY CANCER

Tests that identify the genetic changes that increase the risk of developing hereditary cancer, and if a patient's cancer is caused by an inherited germline mutation.

BENEFITS OF HEREDITARY CANCER TESTING

- Non-invasive and safe for patients
- Identifies germline mutations that increase the risk of developing cancer, or hereditary cancer predisposing syndromes
- Improves the clinical management of the patients, and their family and informs other family members of their risk
- Improves disease classification
- Helps in identifying prophylactic measures for cancer prevention, if applicable

PreSENTIA

Buccal swab

10-15 days

PreSENTIA TESTS

Pan-Cancer	*62 genes*
Breast/Gynecological	*26 genes*
Breast/Gynecological guidelines-based	*19 genes*
Breast high-risk	*7 genes*
BRCA1/BRCA2	*2 genes*
Colorectal	*17 genes*
Colorectal high-risk	*10 genes*
Colorectal non-polyposis syndrome	*5 genes*
Colorectal polyposis syndrome	*7 genes*
Myelodysplastic syndrome/Leukemia	*24 genes*
Gastric	*14 genes*
Prostate	*15 genes*
Pancreatic	*17 genes*
Renal	*13 genes*
Skin (XP-associate)	*9 genes*
Familial melanoma	*7 genes*
Paraganglioma/pheochromocytoma	*6 genes*
Parathyroid	*1 gene*
Thyroid	*1 gene*

Predict&Prevent

EDTA Blood or
Buccal swab

15-25 days

PREDICT&PREVENT TESTS

Comprehensive hereditary cancer panel	*138 genes*
Colon cancer extended panel	*23 genes*
Colon cancer core panel	*17 genes*
Breast and ovarian cancer extended panel	*28 genes*
Breast and ovarian core panel	*18 genes*
Breast and ovarian *BRCA1*, *BRCA2*	*2 genes*
Endocrine tumors	*14 genes*
Fanconi anemia	*22 genes*
Gastrointestinal tumors	*21 genes*
Kidney cancers	*11 genes*
Nervous system/ Brain tumors	*14 genes*
Pancreatic tumors	*15 genes*
Prostate cancer	*11 genes*
Skin tumor	*15 genes*
Unspecific tumor syndromes	*8 genes*

Technological advantages:
The tests are based on technology platforms validated for their precision and accuracy.

ForeSENTIA, Detect&Act, NeoThetis, PreSENTIA, Predict&Prevent

Clinical interpretation of results:
Detailed interpretation of the results on the report, guiding the healthcare providers to identify the best solutions for their patients.

ForeSENTIA, Detect&Act, NeoThetis, PreSENTIA, Predict&Prevent

TECHNOLOGY FEATURES AND SPECIFICATIONS PER TEST

		Liquid biopsy	Somatic tumor profile		Hereditary cancer	
		NeoThetis	ForeSENTIA	Detect&Act	PreSENTIA	Predict& Prevent
Actionability	Available therapies	•	•	•		
	Approved treatments	•	•	•		
	Referral to clinical trials	•	•	•		
	Medical management recommendations	•	•	•	•	•
Technical features and markers analysed	Technology	Target capture enrichment technology via NGS	Target capture enrichment technology via NGS	Hybrid capture-based NGS panel	Target capture enrichment technology via NGS	Exome-based technology via NGS
	TMB	o	o	o		
	MSI	•	o	o		
	SNVs/INDELs	•	•	•	•	•
	CNAs	•	o	•	•	•
	Rearrangements	•	o	o		
	Other biomarkers *Biological molecule that is a sign of a normal or abnormal process, or of a disease*	o	o	o		
	Histopathology		Upon request	o		
	Full exonic coverage *Exceptions apply*	o	o	•	•	•
	Reported variants	•	•	•	•	•
	Variants of unknown clinical significance (VUS) reported	Tier I/II	Tier I/II	Tier I/II	Pathogenic/Likely pathogenic	Pathogenic/Likely pathogenic
	Target selected intronic regions of clinical importance	•	•	•	•	•
	Target splice junction	•	•	•	•	•
Other test details	Turnaround time (TAT)	6-9 days	10-15 days	7-20 days	10-15 days	15-25 days
	Sample type	Blood Sample	FFPE	FFPE	Buccal Swab	Buccal Swab

• Included o Panel applicable

ABOUT MEDICOVER GENETICS

Medicover Genetics is a leading innovator in genetic diagnostics, laboratory enablement, and clinical testing, with over 25 years of experience supporting healthcare systems worldwide. The company offers a comprehensive portfolio of genetic testing services and clinical counselling, supported by certified diagnostic products and platforms.

At the core of its offering is the proprietary Technology Transfer Platform—an end-to-end genomics solution that enables partner laboratories worldwide to perform high-precision genetic tests in-house.

Medicover Genetics' CE-marked, IVDR-certified portfolio, developed through decades of clinical and medical expertise, includes VERACITY™, a non-invasive prenatal test (NIPT), and TarCET™, a suite of clinical assays addressing hereditary cancers, cardiovascular and metabolic disorders, infertility, neonatal conditions, and other critical health areas.

Driven by continuous research and development, Medicover Genetics is actively expanding into advanced areas such as liquid biopsy for therapy selection and minimal residual disease (MRD) testing. Its laboratories are CAP and ISO 15189 accredited, CLIA, ISO 9001, and ISO 13485 certified, and comply with GMP and GCP, ensuring the highest quality standards.

With a presence across Europe, Asia, and Africa, Medicover Genetics collaborates closely with laboratories and clinicians to deliver scalable, high-impact genetic solutions that support personalized medicine and enable informed clinical decision-making. www.medicover-genetics.com

Medicover Genetics is part of Medicover, a leading international healthcare and diagnostic services company founded in 1995 and listed on Nasdaq Stockholm. www.medicover.com

PURPOSE

To empower people to use comprehensive and meaningful genetic tests at the forefront of their diagnostic journey

MISSION

Leverage advancements in genomics to develop relevant diagnostic solutions, supported by professional medical interpretation, to improve people's health and well-being

VISION

To place genetics at the core of medical decisions

VALUES

Humanity • Passion • Medical Excellence • Innovation • Integrity

- Leader in genetic testing with >25 years of experience in counselling and diagnostics
- Provider of turn-key solutions through CE IVD Kits and Technology Transfer Platform for laboratories of any size
- Experienced clinical team providing medically-validated reports and genetic counselling
- Combined with histopathology and clinical laboratory testing
- CAP- accredited and CLIA-, GMP- and ISO9001, 15189 and 13485 certified

CONTACT US

www.medicover-genetics.com
info.genetics@medicover.com

Germany
Lochhamer Str. 29, 82152 Planegg

Cyprus
Neas Engomis 31, 2409 Nicosia

Greece
120 Vas. Sofias, 11526 Athens

MEDICOVER GENETICS